Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for ‘off-the-shelf’ Immunotherapy
Authors:
- R. PreeceRPR. Preece
- O. GoughOGO. Gough
- A. JoshiAJA. Joshi
- R. KadirkamanathanRKR. Kadirkamanathan
- E. CudworthECE. Cudworth
- D. KallonDKD. Kallon
- C. GeorgiadisCGC. Georgiadis
- W. QasimWQW. Qasim
Preprint
Abstract
Chimeric antigen receptor (CAR) T cell therapies are being widely investigated in both autologous and allogeneic settings, with gene editing providing new strategies to address barriers to mismatched cell therapies. Currently ‘universal’ donor derived T cell therapies require intensive lymphodepletion and are prone to host-mediated rejection. CD38, a transmembrane glycoprotein involved in cell activation and bioenergetics, is a promising immunotherapy target for haematological malignancies. Disruption of CD38 expression using base editing prevented fratricide between T cells expressing anti-CD38 CAR (CAR38). Additional base editing enabled generation of a ‘universal’ donor CAR38-T cells, devoid of endogenous TCRαβ and Human Leukocyte Antigen (HLA) molecules after disruption of T Cell Receptor Beta Constant ( TRBC ), Beta-2 microglobulin ( B2M ), and Regulatory Factor X5 ( RFX5 ). Removal of cell surface HLA expression enabled evasion of anti-HLA antibodies in sera from sensitised donors and reduced allo-stimulation in mixed lymphocyte cultures (MLCs), while TCRαβ disruption prevented allo-reactivity. In MLCs, CAR38 expression enabled potent ‘allo-defense’ activity against CD38 + allo-reactive cells. Multiplex-base-edited CAR38-T cells exhibited antigen-specific anti-leukemic activity against human B, T, and myeloid malignancies and inhibited disease progression in humanised murine xenograft models. CAR38-T cells offer a potent ‘off-the-shelf’ strategy against CD38 + haematological malignancies and plasma cells associated with autoimmunity.Keywords
All Related Versions
- Published version: Haematologica.
This publication has 53 references indexed in Scilit:
- CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemiaHeliyon, 2024
- Deletion of CD38 enhances CD19 chimeric antigen receptor T cell functionMolecular Therapy Oncology, 2024
- Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolismCell Reports Medicine, 2024
- CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK CellsAdvanced Science, 2023
- CD38: An important regulator of T cell functionBiomedicine & Pharmacotherapy, 2022
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyThe Lancet, 2021
- Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cellsJournal of Genetics and Genomics, 2019
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity OptimizationMolecular Therapy, 2017
- Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug TreatmentClinical Pharmacokinetics, 2016
- Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: Suggestion for classification by immunophenotype and T-cell receptor studiesLeukemia Research, 1999